List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5188451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases, The, 2020, 20, e192-e197.	9.1	1,165
2	Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour. Critical Care Medicine, 2014, 42, 1749-1755.	0.9	1,159
3	Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respiratory Medicine,the, 2014, 2, 380-386.	10.7	864
4	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	6.7	792
5	Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE, 2020, 15, e0240784.	2.5	634
6	Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA - Journal of the American Medical Association, 2020, 323, 1478.	7.4	419
7	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respiratory Medicine,the, 2021, 9, 622-642.	10.7	371
8	Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Critical Care, 2009, 13, R201.	5.8	316
9	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	2.5	307
10	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
11	Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infectious Diseases, 2018, 5, ofy313.	0.9	255
12	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Medicine, 2021, 47, 188-198.	8.2	237
13	Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Medicine, 2010, 36, 612-620.	8.2	235
14	Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2019, 19, 1299-1311.	9.1	218
15	Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*. Critical Care Medicine, 2007, 35, 1493-1498.	0.9	210
16	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	3.8	208
17	Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infectious Diseases, The, 2019, 19, e422-e436.	9.1	205
18	Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax, 2017, 72, 876-883.	5.6	202

#	Article	IF	CITATIONS
19	Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Annals of the American Thoracic Society, 2021, 18, 997-1003.	3.2	202
20	Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine, 2009, 37, 2360-2369.	0.9	188
21	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenzaÂA infection. Intensive Care Medicine, 2011, 37, 272-283.	8.2	188
22	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. International Journal of Molecular Sciences, 2016, 17, 2120.	4.1	168
23	Community-Acquired Respiratory Coinfection in Critically Ill Patients With Pandemic 2009 Influenza A(H1N1) Virus. Chest, 2011, 139, 555-562.	0.8	164
24	Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Medicine, 2017, 43, 48-58.	8.2	159
25	Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Medicine, 2018, 44, 1400-1426.	8.2	159
26	Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respiratory Medicine,the, 2015, 3, 859-868.	10.7	152
27	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically III Patients*. Critical Care Medicine, 2014, 42, 601-609.	0.9	150
28	Host adaptive immunity deficiency in severe pandemic influenza. Critical Care, 2010, 14, R167.	5.8	145
29	Prolonged elevation of Dâ€dimer levels in convalescent COVIDâ€19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	3.8	142
30	Impact of Source Control in Patients With Severe Sepsis and Septic Shock*. Critical Care Medicine, 2017, 45, 11-19.	0.9	141
31	Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Medicine, 2017, 43, 612-624.	8.2	140
32	Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respiratory Medicine,the, 2016, 4, 882-893.	10.7	137
33	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World Journal of Emergency Surgery, 2016, 11, 33.	5.0	130
34	Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World Journal of Emergency Surgery, 2017, 12, 22.	5.0	130
35	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Medicine, 2019, 45, 789-805.	8.2	127
36	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Medicine, 2018, 44, 1470-1482.	8.2	123

#	Article	IF	CITATIONS
37	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
38	Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection. PLoS ONE, 2012, 7, e38214.	2.5	122
39	Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. Journal of Infection, 2015, 70, 213-222.	3.3	121
40	The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax, 2017, 72, 803-810.	5.6	118
41	Impact of Obesity in Patients Infected With 2009 Influenza A(H1N1). Chest, 2011, 139, 382-386.	0.8	117
42	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	5.8	116
43	Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. Journal of Antimicrobial Chemotherapy, 2011, 66, 1140-1149.	3.0	114
44	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	8.2	114
45	Being Overweight Is Associated With Greater Survival in ICU Patients. Critical Care Medicine, 2015, 43, 2623-2632.	0.9	113
46	Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Medicine, 2018, 44, 449-463.	8.2	113
47	Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376.	9.1	109
48	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. Journal of Infection, 2016, 72, 143-151.	3.3	108
49	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
50	Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Intensive Care Medicine, 2018, 44, 337-344.	8.2	105
51	Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock. Critical Care Medicine, 2018, 46, 1334-1356.	0.9	102
52	Murepavadin: a new antibiotic class in the pipeline. Expert Review of Anti-Infective Therapy, 2018, 16, 259-268.	4.4	100
53	Risk factors for mortality in elderly and very elderly critically ill patients with sepsis: a prospective, observational, multicenter cohort study. Annals of Intensive Care, 2019, 9, 26.	4.6	100
54	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	8.2	100

#	Article	IF	CITATIONS
55	Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. Lancet Regional Health - Europe, The, 2021, 11, 100243.	5.6	99
56	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Medicine, 2018, 44, 438-448.	8.2	96
57	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	2.5	92
58	Decision-Making on Withholding or Withdrawing Life Support in the ICU. Chest, 2017, 152, 321-329.	0.8	90
59	Update of the treatment of nosocomial pneumonia in the ICU. Critical Care, 2020, 24, 383.	5.8	90
60	Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Critical Care, 2011, 15, R62.	5.8	87
61	The role of open abdomen in non-trauma patient: WSES Consensus Paper. World Journal of Emergency Surgery, 2017, 12, 39.	5.0	85
62	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	5.8	85
63	BreathDx – molecular analysis of exhaled breath as a diagnostic test for ventilator–associated pneumonia: protocol for a European multicentre observational study. BMC Pulmonary Medicine, 2017, 17, 1.	2.0	84
64	Nosocomial Infection. Critical Care Medicine, 2021, 49, 169-187.	0.9	82
65	Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive and Critical Care Nursing, 2022, 70, 103227.	2.9	80
66	Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. European Respiratory Journal, 2011, 37, 1332-1339.	6.7	78
67	Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. European Respiratory Journal, 2012, 39, 855-861.	6.7	77
68	New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Current Opinion in Critical Care, 2018, 24, 347-352.	3.2	77
69	d-Dimer elevation and adverse outcomes. Journal of Thrombosis and Thrombolysis, 2015, 39, 55-59.	2.1	75
70	What's new in multidrug-resistant pathogens in the ICU?. Annals of Intensive Care, 2016, 6, 96.	4.6	75
71	Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Medicine, 2009, 35, 430-438.	8.2	73
72	Invasive candidiasis in critical care: challenges and future directions. Intensive Care Medicine, 2020, 46, 2001-2014.	8.2	73

#	Article	IF	CITATIONS
73	More on COVIDâ€19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	2.5	73
74	Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respiratory Medicine,the, 2021, 9, 1377-1386.	10.7	71
75	Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. Critical Care, 2014, 18, 227.	5.8	70
76	Management of severe sepsis: advances, challenges, and current status. Drug Design, Development and Therapy, 2015, 9, 2079.	4.3	70
77	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	8.2	69
78	Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Critical Care, 2021, 25, 177.	5.8	69
79	Meropenem Population Pharmacokinetics in Critically III Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements. Antimicrobial Agents and Chemotherapy, 2015, 59, 5520-5528.	3.2	66
80	Management of the brain-dead donor in the ICU: general and specific therapy to improve transplantable organ quality. Intensive Care Medicine, 2019, 45, 343-353.	8.2	66
81	Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 546-556.	5.6	65
82	Risks for multidrug-resistant pathogens in the ICU. Current Opinion in Critical Care, 2014, 20, 516-524.	3.2	64
83	Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Critical Care, 2014, 18, R129.	5.8	63
84	Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting. Annals of Intensive Care, 2017, 7, 19.	4.6	63
85	Sepsis: frontiers in supportive care, organisation and research. Intensive Care Medicine, 2017, 43, 496-508.	8.2	62
86	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. Journal of Infection, 2020, 81, 131-146.	3.3	62
87	Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. Critical Care, 2012, 16, R223.	5.8	61
88	Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia. Intensive Care Medicine, 2012, 38, 256-262.	8.2	61
89	Efficacy of Single-Dose Antibiotic Against Early-Onset Pneumonia in Comatose Patients Who Are Ventilated. Chest, 2013, 143, 1219-1225.	0.8	59
90	Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection. Respiratory Care, 2017, 62, 1307-1315.	1.6	59

#	Article	IF	CITATIONS
91	Personalized medicine for ARDS: the 2035 research agenda. Intensive Care Medicine, 2016, 42, 756-767.	8.2	58
92	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	3.8	58
93	Corticosteroid therapy in patients with primary viralÂpneumonia due to pandemic (H1N1) 2009Âinfluenza. Journal of Infection, 2012, 64, 311-318.	3.3	57
94	Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Medicine, 2014, 40, 572-581.	8.2	57
95	Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Critical Care, 2021, 25, 63.	5.8	57
96	Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients. Critical Care, 2011, 15, R286.	5.8	56
97	Duration of antibiotic therapy in the intensive care unit. Journal of Thoracic Disease, 2016, 8, 3774-3780.	1.4	56
98	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	3.2	54
99	Influenza Infections and Emergent Viral Infections in Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 488-497.	2.1	54
100	Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC-Antimicrobial Resistance, 2020, 2, dlaa071.	2.1	54
101	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
102	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
103	Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Annals of Intensive Care, 2016, 6, 32.	4.6	50
104	Biomarker-guided antibiotic therapy—strengths and limitations. Annals of Translational Medicine, 2017, 5, 208-208.	1.7	50
105	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Critical Care Medicine, 2021, 49, 598-622.	0.9	49
106	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2019, 45, 1518-1539.	8.2	47
107	Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Critical Care, 2011, 15, R66.	5.8	46
108	Association between timing of intubation and outcome in critically ill patients: A secondary analysis of the ICON audit. Journal of Critical Care, 2017, 42, 1-5.	2.2	46

#	Article	IF	CITATIONS
109	Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. Critical Care, 2022, 26, 11.	5.8	46
110	Bacterial pneumonia as an influenza complication. Current Opinion in Infectious Diseases, 2017, 30, 201-207.	3.1	45
111	Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Review of Anti-Infective Therapy, 2018, 16, 667-677.	4.4	45
112	Procalcitonin levels in candidemia versus bacteremia: a systematic review. Critical Care, 2019, 23, 190.	5.8	45
113	Patient to Nurse Ratio and Risk of Ventilator-Associated Pneumonia in Critically Ill Patients. American Journal of Critical Care, 2011, 20, e1-e9.	1.6	43
114	Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Medicine, 2013, 39, 693-702.	8.2	43
115	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Research, 2018, 4, 00028-2018.	2.6	41
116	Severe 2009 A/H1N1v influenza in pregnant women in Spain*. Critical Care Medicine, 2011, 39, 945-951.	0.9	40
117	First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain. Medicina Intensiva, 2011, 35, 208-216.	0.7	39
118	The Effects of red Blood Cell Transfusion on Tissue Oxygenation and the Microcirculation in the Intensive Care Unit: A Systematic Review. Transfusion Medicine Reviews, 2017, 31, 205-222.	2.0	38
119	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine, 2021, 47, 899-902.	8.2	38
120	Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. Medicina Intensiva, 2016, 40, 238-245.	0.7	37
121	Systemic antibiotics for preventing ventilator-associated pneumonia in comatose patients: a systematic review and meta-analysis. Annals of Intensive Care, 2017, 7, 67.	4.6	36
122	The importance of airway and lung microbiome in the critically ill. Critical Care, 2020, 24, 537.	5.8	36
123	Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. Clinical Microbiology and Infection, 2016, 22, 94.e1-94.e8.	6.0	34
124	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
125	ARDS: challenges in patient care and frontiers in research. European Respiratory Review, 2018, 27, 170107.	7.1	34
126	Management of donation after brain death (DBD) in the ICU: the potential donor is identified, what's next?. Intensive Care Medicine, 2019, 45, 322-330.	8.2	34

#	Article	IF	CITATIONS
127	Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest, 2019, 155, 795-804.	0.8	34
128	The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure. Annals of Intensive Care, 2017, 7, 44.	4.6	33
129	Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. Frontiers in Immunology, 2021, 12, 676932.	4.8	33
130	Sepsis Associated Delirium. Medicina (Lithuania), 2020, 56, 240.	2.0	33
131	Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research 2022 8, 00552-2021	2.6	33
132	Severity assessment tools in ICU patients with 2009 Influenza A (H1N1) pneumonia. Clinical Microbiology and Infection, 2012, 18, 1040-1048.	6.0	31
133	Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes. BMC Research Notes, 2012, 5, 401.	1.4	31
134	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
135	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551.	2.3	31
136	IgM levels in plasma predict outcome in severe pandemic influenza. Journal of Clinical Virology, 2013, 58, 564-567.	3.1	30
137	The volatile metabolic fingerprint of ventilator-associated pneumonia. Intensive Care Medicine, 2014, 40, 761-762.	8.2	30
138	Hospital-Acquired Pneumonia After Lung Resection Surgery Is Associated With Characteristic Cytokine Gene Expression. Chest, 2011, 139, 626-632.	0.8	29
139	COPD patients with ventilator-associated pneumonia: implications for management. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2403-2411.	2.9	29
140	Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections. European Respiratory Journal, 2018, 51, 1701656.	6.7	29
141	Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro. Intensive Care Medicine, 2014, 40, 1945-1949.	8.2	28
142	Incidence and diagnosis of ventilator-associated tracheobronchitis in the intensive care unit: an international online survey. Critical Care, 2014, 18, R32.	5.8	28
143	Current aspects in sepsis approach. Turning things around. Revista Espanola De Quimioterapia, 2018, 31, 298-315.	1.3	28
144	Acute respiratory distress syndrome: prevention and early recognition. Annals of Intensive Care, 2013, 3, 11.	4.6	27

#	Article	IF	CITATIONS
145	Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respiratory Investigation, 2015, 53, 201-209.	1.8	27
146	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS ONE, 2018, 13, e0200504.	2.5	27
147	The Surviving Sepsis Campaign: research priorities for the administration, epidemiology, scoring and identification of sepsis. Intensive Care Medicine Experimental, 2021, 9, 34.	1.9	27
148	Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Critical Care, 2011, 15, 448.	5.8	26
149	Severe pandemic (H1N1)v influenza A infection: Report on the first deaths in Spain. Respirology, 2011, 16, 78-85.	2.3	26
150	Evolution Over a 15-Year Period of Clinical Characteristics and Outcomes of Critically III Patients With Community-Acquired Bacteremia*. Critical Care Medicine, 2013, 41, 76-83.	0.9	26
151	Optimal care and design of the tracheal cuff in the critically ill patient. Annals of Intensive Care, 2014, 4, 7.	4.6	26
152	Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot study. Medicina Intensiva, 2014, 38, 73-82.	0.7	26
153	Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. Journal of Antimicrobial Chemotherapy, 2016, 71, 1651-1659.	3.0	26
154	Relationship between acute kidney injury and serum procalcitonin (PCT) concentration in critically ill patients with influenza infection. Medicina Intensiva, 2018, 42, 399-408.	0.7	26
155	Optimal duration of antibiotic treatment in Gram-negative infections. Current Opinion in Infectious Diseases, 2018, 31, 606-611.	3.1	26
156	An international perspective on hospitalized patients with viral community-acquired pneumonia. European Journal of Internal Medicine, 2019, 60, 54-70.	2.2	26
157	Pacientes con gripe por el virus influenza A (H1N1)pdm09 ingresados en la UCI. Impacto de las recomendaciones de la SEMICYUC. Medicina Intensiva, 2018, 42, 473-481.	0.7	25
158	Clinical controversies in abdominal sepsis. Insights for critical care settings. Journal of Critical Care, 2019, 53, 53-58.	2.2	25
159	Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. Annals of Translational Medicine, 2017, 5, 443-443.	1.7	25
160	Defects in innate and adaptive immunity in patients with sepsis and health care associated infection. Annals of Translational Medicine, 2017, 5, 447-447.	1.7	25
161	Mortality and Regional Oxygen Saturation Index in Septic Shock Patients: A Pilot Study. Journal of Trauma, 2011, 70, 1145-1152.	2.3	24
162	Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenza. BMC Infectious Diseases, 2011, 11, 232.	2.9	24

#	Article	IF	CITATIONS
163	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respiratory Research, 2014, 15, 75.	3.6	24
164	Tools for outcome prediction in patients with community acquired pneumonia. Expert Review of Clinical Pharmacology, 2017, 10, 201-211.	3.1	24
165	Management of invasive candidiasis and candidaemia in critically ill adults: expert opinion of the European Society of Anaesthesia Intensive Care Scientific Subcommittee. Journal of Hospital Infection, 2018, 98, 382-390.	2.9	24
166	Airway Devices in Ventilator-Associated Pneumonia Pathogenesis and Prevention. Clinics in Chest Medicine, 2018, 39, 775-783.	2.1	24
167	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	5.8	24
168	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2021, 159, 58-72.	0.8	24
169	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. European Respiratory Review, 2021, 30, 200346.	7.1	24
170	Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. Journal of Critical Care, 2022, 69, 154014.	2.2	24
171	1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. Respiratory Research, 2022, 23, 115.	3.6	24
172	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. Journal of Critical Care, 2017, 41, 91-97.	2.2	23
173	Choice of fluids in critically ill patients. BMC Anesthesiology, 2018, 18, 200.	1.8	23
174	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. European Respiratory Review, 2020, 29, 200023.	7.1	23
175	Viral Infection is Associated with an Increased Proinflammatory Response in Chronic Obstructive Pulmonary Disease. Viral Immunology, 2012, 25, 249-253.	1.3	22
176	Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the pre-infection period: A pilot study. Medicina Intensiva, 2012, 36, 257-263.	0.7	22
177	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project. ERJ Open Research, 2017, 3, 00092-2017.	2.6	22
178	Potentially modifiable respiratory variables contributing to outcome in ICU patients without ARDS: a secondary analysis of PRoVENT. Annals of Intensive Care, 2018, 8, 39.	4.6	22
179	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	1.4	22
180	Immunological monitoring to prevent and treat sepsis. Critical Care, 2013, 17, 109.	5.8	21

#	Article	IF	CITATIONS
181	Influenza and associated co-infections in critically ill immunosuppressed patients. Critical Care, 2019, 23, 152.	5.8	21
182	Determinants of time to death in hospital in critically ill patients around the world. Intensive Care Medicine, 2016, 42, 1454-1460.	8.2	20
183	Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit. Journal of Critical Care, 2018, 48, 172-177.	2.2	20
184	Frailty is associated with long-term outcome in patients with sepsis who are over 80Âyears old: results from an observational study in 241 European ICUs. Age and Ageing, 2021, 50, 1719-1727.	1.6	20
185	New guidelines for severe community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2021, 27, 210-215.	2.6	20
186	C-reactive protein and procalcitonin profile in ventilator-associated lower respiratory infections. Journal of Critical Care, 2018, 48, 385-389.	2.2	19
187	Relationship between acute kidney injury and serum procalcitonin (PCT) concentration in critically ill patients with influenza infection. Medicina Intensiva (English Edition), 2018, 42, 399-408.	0.2	19
188	Efficacy and safety of antimicrobial de-escalation as a clinical strategy. Expert Review of Anti-Infective Therapy, 2019, 17, 79-88.	4.4	19
189	Effectiveness of an inspiratory pressure-limited approach to mechanical ventilation in septic patients. European Respiratory Journal, 2013, 41, 157-164.	6.7	18
190	Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Review of Anti-Infective Therapy, 2018, 16, 839-847.	4.4	18
191	Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Annals of Intensive Care, 2021, 11, 159.	4.6	18
192	Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients. Journal of Infection, 2022, 85, 374-381.	3.3	18
193	Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis. Expert Review of Clinical Pharmacology, 2017, 10, 457-465.	3.1	17
194	Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically III Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive	0.2	16
195	Care Unit. Medicina Intensiva (English Edition), 2012, 36, 103-137. New definition of sepsis and septic shock: What does it give us?. Medicina Intensiva, 2017, 41, 38-40.	0.7	16
196	How Can We Distinguish Ventilator-Associated Tracheobronchitis from Pneumonia?. Clinics in Chest Medicine, 2018, 39, 785-796.	2.1	16
197	Public awareness of sepsis is still poor: we need to do more. Intensive Care Medicine, 2018, 44, 1771-1773.	8.2	16
198	Checklist for Early Recognition and Treatment of Acute Illness and Injury: An Exploratory Multicenter International Quality-Improvement Study in the ICUs With Variable Resources. Critical Care Medicine, 2021, 49, e598-e612.	0.9	16

#	Article	IF	CITATIONS
199	Choosing antibiotic therapy for severe community-acquired pneumonia. Current Opinion in Infectious Diseases, 2022, 35, 133-139.	3.1	16
200	Clinical characteristics, systemic complications, and in-hospital outcomes for patients with COVID-19 in Latin America. LIVEN-Covid-19 study: A prospective, multicenter, multinational, cohort study. PLoS ONE, 2022, 17, e0265529.	2.5	16
201	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon, 2022, 8, e09230.	3.2	16
202	Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. Intensive Care Medicine Experimental, 2015, 3, 26.	1.9	15
203	Is there a continuum between ventilator-associated tracheobronchitis and ventilator-associated pneumonia?. Intensive Care Medicine, 2016, 42, 1190-1192.	8.2	15
204	The pharmacological management of severe influenza infection – â€~existing and emerging therapies'. Expert Review of Clinical Pharmacology, 2017, 10, 81-95.	3.1	15
205	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. Intensive Care Medicine, 2019, 45, 1753-1762.	8.2	15
206	Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement. Intensive Care Medicine, 2020, 46, 215-224.	8.2	15
207	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine, 2021, 66, 103291.	6.1	15
208	Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes. Current Opinion in Critical Care, 2021, 27, 468-473.	3.2	15
209	Accuracy of the clinical pulmonary infection score to differentiate ventilator-associated tracheobronchitis from ventilator-associated pneumonia. Annals of Intensive Care, 2020, 10, 101.	4.6	15
210	Focus on infection and sepsis in intensive care patients. Intensive Care Medicine, 2016, 42, 491-493.	8.2	14
211	Lower Respiratory Tract Infection and Short-Term Outcome in Patients With Acute Respiratory Distress Syndrome. Journal of Intensive Care Medicine, 2020, 35, 588-594.	2.8	14
212	Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence. Advances in Therapy, 2020, 37, 3083-3096.	2.9	14
213	The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients. Irish Journal of Medical Science, 2021, 190, 1317-1320.	1.5	14
214	Ventilator-associated tracheobronchitis: where are we now?. Revista Brasileira De Terapia Intensiva, 2014, 26, 212-4.	0.3	13
215	Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?. Journal of Clinical Medicine, 2019, 8, 1217.	2.4	13
216	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Research, 2021, 7, 00888-2020.	2.6	13

#	Article	IF	CITATIONS
217	Clinical and biochemical characteristics of patients admitted to ICU with SARS-CoV-2. Medicina Intensiva, 2020, 44, 589-590.	0.7	13
218	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13
219	What Is New in Ventilator-Associated Tracheobronchitis?. Clinical Pulmonary Medicine, 2010, 17, 117-121.	0.3	12
220	Impact of de-escalation on ICU patients' prognosis. Intensive Care Medicine, 2014, 40, 1583-1585.	8.2	12
221	Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine, 2019, 25, 263-270.	2.6	12
222	Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia: The Hidden Enemy?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1071-1073.	5.6	12
223	Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS. Chest, 2020, 158, 1947-1957.	0.8	12
224	What is new in non-ventilated ICU-acquired pneumonia?. Intensive Care Medicine, 2020, 46, 488-491.	8.2	12
225	ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome. Journal of Clinical Medicine, 2022, 11, 224.	2.4	12
226	Efficiency of a mechanical device in controlling tracheal cuff pressure in intubated critically ill patients: a randomized controlled study. Annals of Intensive Care, 2015, 5, 54.	4.6	11
227	Macrolide therapy of pneumonia. Current Opinion in Infectious Diseases, 2016, 29, 212-217.	3.1	11
228	Pre-emptive and therapeutic value of blocking bacterial attachment to the endothelial alphaVbeta3 integrin with cilengitide in sepsis. Critical Care, 2017, 21, 246.	5.8	11
229	Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections. Microorganisms, 2020, 8, 165.	3.6	11
230	Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies. , 2021, 3, e0511.		11
231	Transcriptomic depression of immunological synapse as a signature of ventilator-associated pneumonia. Annals of Translational Medicine, 2018, 6, 415-415.	1.7	11
232	Ventilator-associated pneumonia in critically ill patients with COVID-19 infection: a narrative review. ERJ Open Research, 2022, 8, 00046-2022.	2.6	11
233	Incidence of airway complications in patients using endotracheal tubes with continuous aspiration of subglottic secretions. Annals of Intensive Care, 2017, 7, 109.	4.6	10
234	What's new in restoring the gut microbiota in ICU patients? Potential role of faecalÂmicrobiota transplantation. Clinical Microbiology and Infection, 2018, 24, 803-805.	6.0	10

#	Article	IF	CITATIONS
235	Clinical management of sepsis can be improved by artificial intelligence: no. Intensive Care Medicine, 2020, 46, 378-380.	8.2	10
236	Untargeted Molecular Analysis of Exhaled Breath as a Diagnostic Test for Ventilator-Associated Lower Respiratory Tract Infections (BreathDx). Thorax, 2022, 77, 79-81.	5.6	10
237	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. Lancet Infectious Diseases, The, 2022, 22, e74-e87.	9.1	10
238	Should We Treat Ventilator-Associated Tracheobronchitis with Antibiotics?. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 264-270.	2.1	9
239	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	6.7	9
240	Host-pathogen interaction during mechanical ventilation: systemic or compartmentalized response?. Critical Care, 2019, 23, 134.	5.8	9
241	Acute Respiratory Failure Outcomes in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant: A Secondary Analysis of the EFRAIM Study. Transplantation and Cellular Therapy, 2021, 27, 78.e1-78.e6.	1.2	9
242	Prospective observational study of respiratory <i>Aspergillus</i> colonization or disease in patients with various stages of chronic obstructive pulmonary disease utilizing culture versus nonculture techniques. Medical Mycology, 2021, 59, 557-563.	0.7	9
243	A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial. Trials, 2021, 22, 288.	1.6	9
244	If not now, when? A clinical perspective on the unprecedented challenges facing ICUs during the COVID-19 pandemic. Intensive Care Medicine, 2021, 47, 588-590.	8.2	9
245	Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. Annals of Intensive Care, 2020, 10, 146.	4.6	9
246	From ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2013, 22, 231-237.	0.1	8
247	Formación en Medicina Intensiva. Un reto a nuestro alcance. Medicina Intensiva, 2014, 38, 305-310.	0.7	8
248	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	1.9	8
249	The research agenda in VAP/HAP: next steps. Intensive Care Medicine, 2017, 43, 1389-1391.	8.2	8
250	Antibiotic therapy in the critically ill - expert opinion of the Intensive Care Medicine Scientific Subcommittee of the European Society of Anaesthesiology. European Journal of Anaesthesiology, 2017, 34, 215-220.	1.7	8
251	A way towards ventilator-associated lower respiratory tract infection research. Intensive Care Medicine, 2020, 46, 1504-1505.	8.2	8
252	Prognostic Value of Procalcitonin and C-Reactive Protein in 1608 Critically Ill Patients with Severe Influenza Pneumonia. Antibiotics, 2021, 10, 350.	3.7	8

#	Article	IF	CITATIONS
253	Rates of Aspergillus Co-Infection in COVID Patients in ICU Not as High as Previously Reported. Clinical Infectious Diseases, 2021, 73, e1236-e1238.	5.8	8
254	Long term mortality following sepsis. Annals of Translational Medicine, 2016, 4, 387-387.	1.7	8
255	Ventilator-associated tracheobronchitis: an update. Revista Brasileira De Terapia Intensiva, 2019, 31, 541-547.	0.3	8
256	Autoimmune disease and sickle cell anaemia: â€~Intersecting pathways and differential diagnosis'. British Journal of Haematology, 2022, 197, 518-528.	2.5	8
257	Epidemiology and outcome of pressure injuries in critically ill patients with chronic obstructive pulmonary disease: A propensity score adjusted analysis. International Journal of Nursing Studies, 2022, 129, 104222.	5.6	8
258	Inflammation and Infection in Critical Care Medicine. Mediators of Inflammation, 2014, 2014, 1-2.	3.0	7
259	Extracorporeal membrane oxygenation in an HIV-positive man with severe acute respiratory distress syndrome secondary to pneumocystis and cytomegalovirus pneumonia. International Journal of STD and AIDS, 2018, 29, 198-202.	1.1	7
260	Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?. Journal of Thoracic Disease, 2018, 10, S2133-S2137.	1.4	7
261	Steroids and severe pneumonia. Ready for the winter? Discussion on "Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study― Intensive Care Medicine, 2018, 44, 2319-2320.	8.2	7
262	Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ Open Research, 2019, 5, 00212-2018.	2.6	7
263	Elevated monocyte distribution width in trauma: An early cellular biomarker of organ dysfunction. Injury, 2022, 53, 959-965.	1.7	7
264	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 1166-1177.	3.0	7
265	Overtreating or underdiagnosing invasive pulmonary aspergillosis (IPA) in critically ill H1N1 patients: who is right?. Intensive Care Medicine, 2012, 38, 1733-1735.	8.2	6
266	Grado de adherencia al tratamiento antivÃrico recomendado durante la pandemia y periodo pospandémico de gripe A (H1N1)pdm09 en 148 unidades de cuidados intensivos españolas. Medicina Intensiva, 2015, 39, 222-233.	0.7	6
267	What patient data should be collected in this randomized controlled trial in sepsis?. Intensive Care Medicine, 2016, 42, 2011-2013.	8.2	6
268	Finally time for rapid response systems to be well MET in Europe?. Intensive Care Medicine, 2016, 42, 608-610.	8.2	6
269	Research in community-acquired pneumonia: the next steps. Intensive Care Medicine, 2017, 43, 1395-1397.	8.2	6
270	Focus on infection and sepsis 2017. Intensive Care Medicine, 2017, 43, 867-869.	8.2	6

#	Article	IF	CITATIONS
271	Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration. European Journal of Clinical Pharmacology, 2021, 77, 1169-1180.	1.9	6
272	Practice of adjunctive treatments in critically ill COVID–19 patients—rational for the multicenter observational PRoAcT-COVID study in The Netherlands. Annals of Translational Medicine, 2021, 9, 813-813.	1.7	6
273	Immune System Disequilibrium—Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. Frontiers in Medicine, 2021, 8, 711397.	2.6	6
274	Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU. Medicina Intensiva (English Edition), 2021, 45, 485-500.	0.2	6
275	Elevated Rates of Ventilator-Associated Pneumonia and COVID-19 Associated Pulmonary Aspergillosis in Critically III Patients with SARS-CoV2 Infection in the Second Wave: A Retrospective Chart Review. Antibiotics, 2022, 11, 632.	3.7	6
276	A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia. Critical Care, 2012, 17, 106.	5.8	5
277	Extracorporeal lung support in patients with severe respiratory failure secondary to the 2010–2011 winter seasonal outbreak of influenza A (H1N1) in Spain. Medicina Intensiva (English Edition), 2012, 36, 193-199.	0.2	5
278	Innovations that could improve early recognition of ventilator-associated pneumonia. Intensive Care Medicine, 2014, 40, 1352-1354.	8.2	5
279	In the name of ventilator-associated pneumonia prevention: lung microbiota blown away by colistin!. European Respiratory Journal, 2015, 46, 1544-1547.	6.7	5
280	Neces-SARI-ly?. Intensive Care Medicine, 2016, 42, 928-930.	8.2	5
281	Intensive care medicine in 2050: nanotechnology. Emerging technologies and approaches and their impact on critical care. Intensive Care Medicine, 2018, 44, 1299-1301.	8.2	5
282	Current Concepts in Community and Ventilator Associated Lower Respiratory Tract Infections in ICU Patients. Antibiotics, 2020, 9, 380.	3.7	5
283	Efficacy and appropriateness of novel antibiotics in response to antimicrobial-resistant gram-negative bacteria in patients with sepsis in the ICU. Expert Review of Anti-Infective Therapy, 2022, 20, 513-531.	4.4	5
284	Association of Time–Varying Intensity of Ventilation With Mortality in Patients With COVIDâ^'19 ARDS: Secondary Analysis of the PRoVENT–COVID Study. Frontiers in Medicine, 2021, 8, 725265.	2.6	5
285	Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units. Medicina Intensiva (English Edition), 2022, 46, 81-89.	0.2	5
286	Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit. Expert Opinion on Investigational Drugs, 2022, 31, 173-192.	4.1	5
287	Are preoperative oral care bundles needed to prevent postoperative pneumonia?. Intensive Care Medicine, 2014, 40, 109-110.	8.2	4
288	Contrast-enhanced signs of cardiac arrest during CT. Medicina Intensiva, 2015, 39, 261.	0.7	4

#	Article	IF	CITATIONS
289	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. Intensive Care Medicine Experimental, 2018, 6, 42.	1.9	4
290	Patients with influenza A (H1N1)pdm09 admitted to the ICU. Impact of the recommendations of the SEMICYUC. Medicina Intensiva (English Edition), 2018, 42, 473-481.	0.2	4
291	Current Challenges in the Management of Sepsis in ICUs in Resource-Poor Settings and Suggestions for the Future. , 2019, , 1-24.		4
292	Antibiotic prophylaxis in the ICU: to be or not to be administered for patients undergoing procedures?. Intensive Care Medicine, 2020, 46, 364-367.	8.2	4
293	Influenza management with new therapies. Current Opinion in Pulmonary Medicine, 2020, 26, 215-221.	2.6	4
294	The Prognostic Value of Brain Dysfunction in Critically III Patients with and without Sepsis: A Post Hoc Analysis of the ICON Audit. Brain Sciences, 2021, 11, 530.	2.3	4
295	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. Annals of the American Thoracic Society, 2021, 18, 807-814.	3.2	4
296	Mortality associated with early changes in ARDS severity in COVID–19 patients – Insights from the PRoVENT–COVID study. Journal of Critical Care, 2021, 65, 237-245.	2.2	4
297	Disease-specific gaps within fungal respiratory tract infections: clinical features, diagnosis, and management in critically ill patients. Current Opinion in Pulmonary Medicine, 2022, 28, 218-224.	2.6	4
298	A blueprint for improving undergraduate education in intensive care medicine. Critical Care, 2016, 20, 212.	5.8	3
299	SEPsis REcognition and MAnagement (SEPREMA survey). Intensive Care Medicine, 2016, 42, 477-478.	8.2	3
300	On the verge of using an immune toolbox in the intensive care unit?. Intensive Care Medicine, 2017, 43, 1154-1156.	8.2	3
301	In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model. Expert Opinion on Drug Delivery, 2017, 14, 1447-1453.	5.0	3
302	Will all ARDS patients be receiving mechanical ventilation in 2035? Yes. Intensive Care Medicine, 2017, 43, 568-569.	8.2	3
303	Feasibility of Antimicrobial Stewardship (AMS) in Critical Care Settings: A Multidisciplinary Approach Strategy. Medical Sciences (Basel, Switzerland), 2018, 6, 40.	2.9	3
304	Source control and intra-abdominal infections: Still many questions and only limited answers. Journal of Critical Care, 2019, 52, 265-266.	2.2	3
305	Improved Endotracheal Tubes for Prevention of Ventilator-Associated Pneumonia: Better Than Silver and Gold?. Respiratory Care, 2019, 64, 108-109.	1.6	3
306	Conventional amphotericin B must be avoided in Candida infections. Intensive Care Medicine, 2020, 46, 560-561.	8.2	3

#	Article	IF	CITATIONS
307	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. Expert Review of Anti-Infective Therapy, 2021, 19, 759-767.	4.4	3
308	Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study. European Respiratory Journal, 2022, 59, 2100620.	6.7	3
309	Surgical antimicrobial prophylaxis in intensive care unit (ICU) patients: a preliminary, observational, retrospective study. Annals of Translational Medicine, 2018, 6, 402-402.	1.7	3
310	HAP and VAP after Guidelines. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 248-254.	2.1	3
311	Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia. Medicina Intensiva, 2022, 46, 426-435.	0.7	3
312	The Incidence of Venous Thromboembolism in Critically III Patients with SARS-CoV-2 Infection Compared with Critically III Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review. Medical Sciences (Basel, Switzerland), 2022, 10, 30.	2.9	3
313	NeumonÃa adquirida en la comunidad: variantes génicas implicadas en la inflamación sistémicamación sistémica. Medicina Intensiva, 2014, 38, 315-323.	0.7	2
314	IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia. Journal of Clinical Virology, 2014, 59, 135-136.	3.1	2
315	Training in Intensive Care Medicine. A challenge within reach. Medicina Intensiva (English Edition), 2014, 38, 305-310.	0.2	2
316	Biomarker Kinetics in VAP. Clinical Pulmonary Medicine, 2015, 22, 185-191.	0.3	2
317	Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain. Medicina Intensiva (English) Tj ETQq1 1	0.ø & 4314	r g BT /Overic
318	Collinearity and multivariable analysis: response to comments by Claret et al Intensive Care Medicine, 2016, 42, 1835-1835.	8.2	2
319	Selection of right studies criteria to foster conclusions. Caveats for metanalysis conducted in sepsis. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 64-65.	1.6	2
320	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. Breathe, 2017, 13, 209-215.	1.3	2
321	Thinking forward: promising but unproven ideas for future intensive care. Critical Care, 2019, 23, 197.	5.8	2
322	CandidaProphylaxis and Treatment in Critically III Patients after Abdominal Surgery: A Survey of Practice. Surgical Infections, 2019, 20, 510-518.	1.4	2
323	The European Network for ICU-Related Respiratory Infections (ENIRRIs) ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1801972.	6.7	2
324	Future of the ICU: finding treatable needles in the data haystack. Intensive Care Medicine, 2019, 45, 240-242.	8.2	2

#	Article	IF	CITATIONS
325	From the ICU to the operating room: how to manage the patient?. Current Opinion in Anaesthesiology, 2020, 33, 139-145.	2.0	2
326	Antifungal use in the surgical ICU patient. Current Opinion in Anaesthesiology, 2020, 33, 131-138.	2.0	2
327	Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia. Expert Review of Anti-Infective Therapy, 2020, 18, 1177-1185.	4.4	2
328	Clinical and biochemical characteristics of patients admitted to ICU with SARS-CoV-2. Medicina Intensiva (English Edition), 2020, 44, 589-590.	0.2	2
329	Feasibility of Telephone Follow-Up after Critical Care Discharge. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 r	gBT (Overle	ock 10 Tf 50
330	Ventilation practices in burn patients—an international prospective observational cohort study. Burns and Trauma, 2021, 9, tkab034.	4.9	2
331	Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. Antibiotics, 2021, 10, 798.	3.7	2
332	Bacteremia in critically ill immunocompromised patients with acute hypoxic respiratory failure: A post-hoc analysis of a prospective multicenter multinational cohort. Journal of Critical Care, 2021, 64, 114-119.	2.2	2
333	Severe infections in neurocritical care. Current Opinion in Critical Care, 2021, 27, 131-138.	3.2	2
334	Management of Severe Influenza. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 771-787.	2.1	2
335	Current status of fiberoptic bronchoscopy in intensive care medicine. Medicina Intensiva (English) Tj ETQq1 1 0.7	784314 rgt 0.2	3T ₁ /Overlock
336	Contrast-enhanced signs of cardiac arrest during CT. Medicina Intensiva (English Edition), 2015, 39, 261.	0.2	1
337	Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. Medicina Intensiva (English Edition), 2016, 40, 238-245.	0.2	1
338	What were you able to do in your daily life? Performance status for the critically ill patient. Intensive Care Medicine, 2017, 43, 104-106.	8.2	1
339	Beat around the bush for VA-LRTI. Intensive Care Medicine, 2018, 44, 1961-1963.	8.2	1
340	MRI Assessment of Global and Regional Diaphragmatic Motion in Critically III Patients Following Prolonged Ventilator Weaning. Medical Sciences (Basel, Switzerland), 2019, 7, 66.	2.9	1
341	38: CERTAIN: AN INTERNATIONAL QUALITY IMPROVEMENT STUDY IN THE INTENSIVE CARE UNIT. Critical Care Medicine, 2019, 47, 19-19.	0.9	1
342	Focus on infection. Intensive Care Medicine, 2020, 46, 787-789.	8.2	1

#	Article	IF	CITATIONS
343	Acute respiratory failure in immunosuppressed patients admitted to ICU. Journal of Critical Care, 2021, 63, 26-31.	2.2	1
344	Integrative research agenda for diagnosis in sepsis. Annals of Translational Medicine, 2017, 5, 454-454.	1.7	1
345	The significance of clinical scores and biological markers in disease severity, mortality prediction, and justifying hospital admissions in patients with community-acquired pneumonia. Community Acquired Infection, 2016, 3, 36.	0.1	1
346	Evaluation of Respiratory Sequelae in Patients With COVID-19, Where we are and Where we are Going. CIBERESUCICOVID and RECOVID Studies to Compare Patients Admitted to ICU vs Conventional Ward. Archivos De Bronconeumologia, 2022, 58, T115-T116.	0.8	1
347	Reply to Westley and Chan and to Shih et al Intensive Care Medicine, 2010, 36, 1789-1790.	8.2	0
348	First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain. Medicina Intensiva (English Edition), 2011, 35, 208-216.	0.2	0
349	Severe Pandemic (H1N1) Influenza A Infection. Clinical Pulmonary Medicine, 2011, 18, 14-19.	0.3	0
350	Current Key Points in Management for Severe Community-Acquired Pneumonia. Current Respiratory Medicine Reviews, 2011, 7, 250-256.	0.2	0
351	Reply to Petros et al.: Early steriod therapy for patients with H1N1 influenza A virus infection. Intensive Care Medicine, 2011, 37, 1565-1565.	8.2	0
352	Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the pre-infection period: A pilot study. Medicina Intensiva (English) Tj ETQq0 0 0	rgBT0/Øverl	ocko10 Tf 50
353	Genetic Polymorphisms of Systemic Inflammation in Community-acquired Pneumonia. Clinical Pulmonary Medicine, 2013, 20, 69-76.	0.3	0
354	Antibiotic Prophylaxis for Ventilator-Associated Pneumonia: Response. Chest, 2013, 144, 1735.	0.8	0
355	Community acquired pneumonia: Genetic variants influencing systemic inflammation. Medicina Intensiva (English Edition), 2014, 38, 315-323.	0.2	0
356	Impact of non-invasive mechanical ventilation (niv) in critical patients with influenza (H1N1) PDM09. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
357	Pneumococcal pneumonia coinfection in critically ill patients with influenza a (h1n1) primary viral pneumonia. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
358	Coagulopathy in fulminant liver failure with ultimately fatal clot formation. Intensive Care Medicine, 2016, 42, 1628-1629.	8.2	0
359	Toward a personalized response approach in sepsis 4.0. Medicina Intensiva (English Edition), 2017, 41, 55-56.	0.2	0
360	Toward a personalized response approach in sepsis 4.0. Medicina Intensiva, 2017, 41, 55-56.	0.7	0

#	Article	IF	CITATIONS
361	Community-Acquired Pneumonia. Chest, 2018, 153, 762-763.	0.8	0
362	Influenza A: New Therapeutic Targets for a Deadly Disease. Archivos De Bronconeumologia, 2019, 55, 295-296.	0.8	0
363	Influenza A: New Therapeutic Targets for a Deadly Disease. Archivos De Bronconeumologia, 2019, 55, 295-296.	0.8	Ο
364	Focus on infection. Intensive Care Medicine, 2019, 45, 1127-1129.	8.2	0
365	Accuracy of the Clinical Pulmonary Infection Score to Differentiate Ventilator Associated Tracheobronchitis from Ventilator Associated Pneumonia. , 2020, , .		Ο
366	ICU-acquired pneumonia in immunosuppressed patients with acute hypoxemic respiratory failure: A post-hoc analysis of a prospective international cohort study. Journal of Critical Care, 2021, 63, 243-245.	2.2	0
367	Prior influenza vaccine is not a risk factor for bacterial coinfection in patients admitted to the ICU due to severe influenza. Medicina Intensiva, 2021, , .	0.7	Ο
368	Corticosteroids and RCTs against the supposed undervaluation of real data evidence. Critical Care, 2021, 25, 297.	5.8	0
369	Ventilator-Associated Tracheobronchitis. , 2022, , 530-535.		0
370	Challenges in Severe Influenza Pneumonia. , 2022, , 350-361.		0
371	A New Approach to Ventilator-associated Pneumonia Based on the PIRO System. Annual Update in Intensive Care and Emergency Medicine, 2011, , 481-492.	0.2	0
372	What is new in severe sepsis in the critically ill patient?. Annals of Translational Medicine, 2017, 5, 442-442.	1.7	0
373	Hot topics in ventilator-associated pneumonia. Annals of Translational Medicine, 2018, 6, 414-414.	1.7	0
374	From the macro to the micro. Diagnosis at first glance. Medicina Intensiva, 2020, , .	0.7	0